The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor xa inhibitor

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 2, 2013, Pages 212-221

  Mendell, Jeanne ^a   Lee, Frank ^b   Chen, Shuquan ^a   Worland, Valerie ^b   Shi, Minggao ^a   Samama, Meyer M ^c,d  

^a DAIICHI SANKYO INC   (United States)

^b CELERION   (United States)

^c HÔTEL DIEU   (France)

^d Biomnis Laboratory   (France)

Author keywords

anticoagulant; Antiplatelet; bleeding times; edoxaban; pharmacokinetics; platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; EDOXABAN; NAPROXEN;

ADULT; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BODY MASS; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; BLOOD PHYSIOLOGICAL PHENOMENA; COHORT STUDIES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; PLATELET AGGREGATION INHIBITORS; PYRIDINES; THIAZOLES; YOUNG ADULT;

EID: 84883301339     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182970991     Document Type: Article

References (34)

1. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-276.
2. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31: 2369-2429.
3. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.
4. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke. 2010;41:2705-2713.
5. Potpara TS, Lip GY. Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: Focus on atrial fibrillation. Curr Pharm Des. 2010;16:3455-3471.
6. Daiichi Sankyo Inc, US National Institutes of Health. Comparative investigation of low molecular weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots (The Edoxaban Hokusai-VTE Study). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available at: Http://clinicaltrials.gov/ct2/show/NCT00986154. Accessed August 1, 2012.
7. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542-1549.
8. Daiichi Sankyo Inc, the TIMI Study Group. Global study to assess the safety and effectiveness of DU-176b vs standard practice of dosing with warfarin in patients withatrial fibrillation (ENGAGE AF TIMI-48). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); Available at: Http://clinicaltrials.gov/show/NCT00781391. Accessed August 1, 2012.
9. Hutt AJ, Caldwell J, Smith RL. The metabolism of aspirin in man: A population study. Xenobiotica. 1986;16:239-249.
10. Runkel R, Chaplin M, Boost G, et al. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 1972;61:703-708.
11. Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250-2255.
12. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50: 743-753.
13. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-641.
14. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100: 1419-1426.
15. Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152: 967-973.
16. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257-e354.
17. Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51:687-694.
18. Wolzt M, Samama MM, Kapiotis S, et al. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost. 2011;105:1080-1090.
19. Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem. 2004;11:2245-2260.
20. Gladding PA, WebsterMW, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101:1060-1063.
21. Schiff M, Hochberg MC, Oldenhof J, et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin. 2009;25:2471-2477.
22. Loncar R, Kalina U, Stoldt V, et al. Antithrombin significantly influences platelet adhesion onto immobilized fibrinogen in an in-vitro system simulating low flow. Thromb J. 2006;4:19.
23. Fisher M, Knappertz V. The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Curr Med Res Opin. 2006;22: 1239-1248.
24. Weisman SM, Graham DY. Evaluation of the benefits and risks of lowdose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197-2202.
25. Barton GR, Avery AJ, Whynes DK. Accounting for the increase in NSAID expenditure: Substitution or leakage? Cost Eff Resour Alloc. 2006;4:9.
26. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708.
27. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
28. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121: 1523-1532.
29. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-An oral, direct factor Xa inhibitor-Are not affected by aspirin. J Clin Pharmacol. 2006;46:981-990.
30. Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939)-An oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63:469-476.
31. Lind SE. Prolonged bleeding time. Am J Med. 1984;77:305-312.
32. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thomb Hemost. 1990;16:1-20.
33. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost. 2008;6:1736-1741.
34. Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl. 2005;6:13-19.